Convatec's H1 2026: A Second Impairment in Skin Substitutes, but Infusion Care Carries the Momentum

InnovaMatrix is written down again, but the company sees double-digit Infusion Care growth in H2 and reaffirms a 23%+ margin guide.

CTEC.L · Earnings Call · 2026-08-04

The InnovaMatrix Reset

Convatec's skin substitutes business is no longer a growth story; it is a write-off. First-half sales fell to $2.5 million from $39.5 million a year ago, triggering a $69 million noncash impairment. “InnovaMatrix sales decreased $37 million year-on-year to $2.5 million in the first half, which represented just over 3% headwind to group revenue growth” — Fiona Ryder, CFO · 2026-08-04 The new full-year guide of $5–10 million is a sharp cut from the $20 million management had forecast in February. CEO Jonathan Mason was blunt about the market: “The first half was very challenging. The diabetic foot market -- foot ulcer market, in particular, in the physician's office is basically frozen at the moment.” — Jonathan Mason, CEO · 2026-08-04 He argues this is a temporary dislocation caused by CMS pricing and audit activity, and that the technology works, but the company is no longer depending on it. That uncertainty is why Convatec has cut expectations so aggressively and why it now treats InnovaMatrix as just one of 16 new products rather than a standalone growth driver.

Infusion Care: The Engine That Still Works

The counterweight is Infusion Care, where organic growth hit 7.4% in H1 and management is guiding to double-digit growth in H2, backed by purchase orders. In the Q&A, the CEO confirmed the visibility is real:

We have good visibility over the second half of the year. We're feeling confident we'll get where we've guided and that, that will form a very strong base for the acceleration in 2027 and beyond.
Jonathan Mason, CEO · 2026-08-04

That confidence is predicated on capacity expansion; the company is spending aggressively to add Infusion Care capacity, though most of it arrives in 2027. The faster growth story also rests on diversification beyond diabetes—Parkinson's disease infusion sets for AbbVie, Tanabe, and Supernus are now a meaningful part of the mix. This is a clear strategic pivot: the old dependence on insulin pump sets is being supplemented by a multi-therapy pipeline. Prior to this strong H1, the CEO had already signaled the pattern: “The customer orders are predictable, but not uniform, right? They are a bit lumpy, but we know what they are because we talk very closely, work very closely with our customers.” — Jonathan Mason, Chief Executive Officer · 2026-02-24

Margin and Capital Returns

Operating margin fell 10bp year-on-year to 21.2% (up 50bp at constant currency), but the company reaffirmed its at-least-23% full-year guidance. Its bridge to H2 hinges on seasonality, Infusion Care phasing, and productivity gains. The company also announced a $200 million buyback—its second in less than a year—after the $300 million program completed in 2025. With interim dividend up 15% and leverage expected to settle at ~2x, Convatec is signaling that the growth story is intact despite the InnovaMatrix setback.

FDA Observations and the Broader Picture

The FDA warning letter on Infusion Care quality management remains an overhang, but management insists there is no product safety issue and that the agency is reviewing the whole insulin supply chain. “the FDA has looked at the whole insulin supply chain. So we're not the only one with one of these letters.” — Jonathan Mason, CEO · 2026-08-04 The company expects the letter to remain in place through 2027, but it does not impact manufacturing or sales. Meanwhile, new product momentum continues: ConvaNiox, a premium wound dressing, is being positioned as a platform with potential to become the brand's biggest product, and Esteem Body is already annualizing at $60 million. The investment in capacity across all four categories—not just Infusion Care—underscores a belief that the 6–8% organic growth target is achievable from 2027.But the most notable shift is the company's willingness to let go of its skin substitute dream. In February, the tone was still optimistic: “we have taken prudent and risk-adjusted forecasts and the impairment that has fallen out is $72 million” — Fiona Ryder, Chief Financial Officer · 2026-02-24—that was the first write-down. Now, with a second impairment and a 75% cut to guidance, management is acknowledging that the market has not healed. The key question for investors is whether the Infusion Care acceleration can offset this drag—and whether the company's disciplined capital returns give them time to wait for the wound market to recover.